Drug intelligence / Profile preview

Photocil

Development stage: Unknown
Lead developer: CBRA
Modality: Small Molecules
Administration: Topical

Overview

Photocil is a novel topical cream designed to selectively filter solar radiation, delivering narrow-band ultraviolet B (NB-UVB) therapy with a peak transmission of 308nm while protecting the skin from non-therapeutic UVB radiation. Developed by Applied Biology (acquired by Jupiter Wellness), it serves as a convenient alternative to traditional artificial light phototherapy for inflammatory skin conditions. The drug is primarily investigated for the treatment of psoriasis, atopic dermatitis, and vitiligo, aiming to improve patient compliance by allowing for phototherapy through natural sunlight exposure.

Brand names: Photocil
Other names: Photocil

Beyond the preview

Go deeper on Photocil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Photocil.

Explore the full profile